Italian pharmaceutical company Dipharma has completed construction of a new quality control laboratory and manufacturing, or kilolab, facility for its Kalexsyn Inc. subsidiary in Kalamazoo.
The state-of-the-art manufacturing suite strengthens Dipharma’s contract development and manufacturing organization (CDMO) offering and completes the range of services, ensuring continuity across the whole lifecycle of customers’ molecules, from preclinical to commercial stage.
The quality control lab is designed and equipped according to latest pharmaceutical quality standards, with full regulatory compliance for data integrity management.
“The new suite marks the achievement of a key milestone within the exclusive synthesis growth strategy and reinforces the company’s value proposition to provide reliable innovative solutions to customers,” says Jorge Nogueira, CEO of Dipharma. “Dipharma Group is now able to cover the whole pharmaceutical chemistry services spectrum, from discovery to marketed drugs.”
